StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note issued to investors on Monday. The firm issued a sell rating on the stock.
Several other research analysts have also recently issued reports on the stock. Maxim Group decreased their price objective on shares of Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a report on Tuesday, March 26th. Roth Mkm reiterated a buy rating and issued a $40.00 price objective on shares of Moleculin Biotech in a report on Friday, April 12th.
Moleculin Biotech Stock Performance
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last posted its earnings results on Friday, May 10th. The company reported ($2.02) EPS for the quarter, topping the consensus estimate of ($3.59) by $1.57. Equities research analysts expect that Moleculin Biotech will post -8.79 earnings per share for the current fiscal year.
Institutional Trading of Moleculin Biotech
A hedge fund recently bought a new stake in Moleculin Biotech stock. Atticus Wealth Management LLC bought a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned approximately 0.17% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 15.52% of the stock is owned by institutional investors and hedge funds.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
See Also
- Five stocks we like better than Moleculin Biotech
- CD Calculator: Certificate of Deposit Calculator
- Sales Breakout Sends This Semiconductor Stock to Record High
- There Are Different Types of Stock To Invest In
- Surprise Buying Opportunity on This Dividend Aristocrat
- How to invest in marijuana stocks in 7 steps
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.